

## Rhythm Biosciences March 2018 Appendix 4C

Rhythm Biosciences (“Rhythm” or the “Company” ASX: RHY), developer of the ColoSTAT™ antibody-based blood test targeting the accurate and early detection of colorectal cancer, is pleased to present the attached Appendix 4C for the quarter ended 31 March 2018.

The quarter saw the Company deliver the following operational highlights:

- Contract signed with CSIRO for reagent development
- Development of reagents for two ColoSTAT biomarkers complete
- Key reagents development for third ColoSTAT biomarker anticipated to be completed according to schedule
- Development pathway of IVD kit on schedule & consultation with major diagnostic laboratories underway
- Rhythm remains well-funded with a cash position of \$8.2M at the end of the March 2018 quarter

**For further information, please contact:**

**TREVOR LOCKETT**  
MANAGING DIRECTOR  
0418 647 490

**SHANE TANNER**  
CHAIRMAN  
0411 107 099

### **About Rhythm Biosciences**

Rhythm Biosciences is developing and commercialising Australian medical diagnostics technology for sale across national and international markets.

Rhythm’s lead product, ColoSTAT™, is intended to provide the accurate and early detection of colorectal cancer, acting as either a ‘first-step’ screening test or within the triage of persons with a positive faecal immunochemical test (FIT) or colonoscopy. As well as being of value to those with risk factors associated with colorectal cancer, ColoSTAT™ provides an alternative for those who choose not to or are unable to be assessed using standard screening programs.

Being developed to be an affordable and effective diagnostic, ColoSTAT™ has the potential to play an important role in reducing morbidity, mortality and healthcare costs associated with colorectal cancer.

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

RHYTHM BIOSCIENCES LIMITED

**ABN**

59 619 459 335

**Quarter ended ("current quarter")**

31 MARCH 2018

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date ( 9 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	(242)	(428)
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs	(28)	(86)
(f) administration and corporate costs	(284)	(585)
1.3 Dividends received (see note 3)		
1.4 Interest received		1
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(554)</b>	<b>(1,098)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment		(4)
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date ( 9 months) \$A'000
(d) intellectual property		(311)
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment		
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
<b>2.6 Net cash from / (used in) investing activities</b>	-	<b>(315)</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares		9,042
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options		(885)
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
<b>3.10 Net cash from / (used in) financing activities</b>	-	<b>8,157</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	8,793	1,495
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(554)	(1,098)
4.3 Net cash from / (used in) investing activities (item 2.6 above)		(315)
4.4 Net cash from / (used in) financing activities (item 3.10 above)		8,157

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date ( 9 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held		
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>8,239</b>	<b>8,239</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	1,239	8,793
5.2	Call deposits	7,000	
5.3	Bank overdrafts		
5.4	Other (provide details)		
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>8,239</b>	<b>8,793</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter \$A'000</b>
123
0

--

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

<b>Current quarter \$A'000</b>

--

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities		
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	730
9.2 Product manufacturing and operating costs	
9.3 Advertising and marketing	15
9.4 Leased assets	
9.5 Staff costs	53
9.6 Administration and corporate costs	233
9.7 Other (provide details if material)	
<b>9.8 Total estimated cash outflows</b>	<b>1,031</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

